AURA

MKT CAP:$480M

Aura Biosciences, Inc.

Market Cap

$480M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.49+$2.19 (+41.32%)

Apr 22, 2026

Company Details

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic onc...

CEO

Elisabet de los Pinos

IPO Date

Oct 29, 2021

Website

www.aurabiosciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$106M

EPS (Diluted)

-$1.82

Free Cash Flow

-$85M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 30, 2026

$0EPS -$1.76

Q4 2025

Mar 30, 2026

$0EPS -$0.40

Q3 2025

Nov 13, 2025

$0EPS -$0.40

Q2 2025

Aug 13, 2025

$0EPS -$0.47

Q1 2025

May 15, 2025

$0EPS -$0.55

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$13M
Q2 22	$0	$0	-$14M
Q3 22	$0	$0	-$16M
Q4 22	$0	$0	-$18M
Q1 23	$0	$0	-$19M
Q2 23	$0	$0	-$20M
Q3 23	$0	$0	-$20M
Q4 23	$0	-$324.0K	-$25M
Q1 24	$0	-$306.0K	-$22M
Q2 24	$0	$0	-$23M
Q3 24	$0	$0	-$23M
Q4 24	$0	-$291.0K	-$28M
Q1 25	$0	$0	-$29M
Q2 25	$0	-$300.0K	-$29M
Q3 25	$0	-$300.0K	-$28M
Q4 25	$0	$600.0K	-$27M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$15M	-$16M
Q2 22	-$11M	-$11M
Q3 22	-$11M	-$11M
Q4 22	-$18M	-$18M
Q1 23	-$16M	-$17M
Q2 23	-$15M	-$15M
Q3 23	-$15M	-$15M
Q4 23	-$17M	-$18M
Q1 24	-$24M	-$25M
Q2 24	-$16M	-$17M
Q3 24	-$15M	-$16M
Q4 24	-$24M	-$24M
Q1 25	-$23M	-$24M
Q2 25	-$21M	-$21M
Q3 25	-$20M	-$20M
Q4 25	-$20M	-$21M

Capital Expenditures

Quarter	CapEx
Q1 22	$599.0K
Q2 22	$74.0K
Q3 22	$63.0K
Q4 22	$358.0K
Q1 23	$109.0K
Q2 23	$193.0K
Q3 23	$90.0K
Q4 23	$317.0K
Q1 24	$88.0K
Q2 24	$525.0K
Q3 24	$341.0K
Q4 24	$299.0K
Q1 25	$187.0K
Q2 25	$39.0K
Q3 25	$45.0K
Q4 25	$176.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+116.1%
Q2 22	—	+57.0%
Q3 22	—	+80.5%
Q4 22	—	+51.5%
Q1 23	—	+51.8%
Q2 23	—	+46.8%
Q3 23	—	+27.6%
Q4 23	—	+40.7%
Q1 24	—	+14.8%
Q2 24	—	+12.3%
Q3 24	—	+13.4%
Q4 24	—	+12.2%
Q1 25	—	+30.1%
Q2 25	—	+25.7%
Q3 25	—	+20.1%
Q4 25	—	-2.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$0	—
Q3 23	$2M	—
Q4 23	$3M	—
Q1 24	$3M	—
Q2 24	$3M	—
Q3 24	$3M	—
Q4 24	$3M	—
Q1 25	$4M	—
Q2 25	$4M	—
Q3 25	$4M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$8M	$5M	—
Q2 22	$10M	$4M	—
Q3 22	$11M	$5M	—
Q4 22	$13M	$4M	—
Q1 23	$14M	$5M	—
Q2 23	$15M	$5M	—
Q3 23	$15M	$5M	—
Q4 23	$20M	—	$4M
Q1 24	$17M	$5M	—
Q2 24	$17M	$6M	—
Q3 24	$17M	$6M	—
Q4 24	$22M	—	$5M
Q1 25	$23M	$6M	—
Q2 25	$23M	$6M	—
Q3 25	$22M	—	$5M
Q4 25	$22M	$5M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$108M	$25M	$133M
Q2 22	$54M	$68M	$122M
Q3 22	$61M	$50M	$112M
Q4 22	$122M	$67M	$189M
Q1 23	$38M	$135M	$174M
Q2 23	$48M	$114M	$162M
Q3 23	$56M	$93M	$149M
Q4 23	$41M	$185M	$226M
Q1 24	$26M	$177M	$203M
Q2 24	$30M	$157M	$187M
Q3 24	$25M	$149M	$174M
Q4 24	$32M	$119M	$151M
Q1 25	$38M	$90M	$128M
Q2 25	$107M	$70M	$177M
Q3 25	$48M	$114M	$162M
Q4 25	$60M	$85M	$144M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	29M	+4.3%	+49.3%
Q2 22	29M	+0.1%	+49.5%
Q3 22	29M	+0.1%	+4.5%
Q4 22	32M	+8.8%	+13.7%
Q1 23	38M	+18.6%	+29.3%
Q2 23	38M	+0.2%	+29.4%
Q3 23	38M	+0.9%	+30.4%
Q4 23	44M	+16.4%	+39.5%
Q1 24	49M	+11.3%	+30.9%
Q2 24	50M	+0.2%	+30.9%
Q3 24	50M	+0.2%	+30.1%
Q4 24	50M	-0.0%	+11.7%
Q1 25	50M	+1.0%	+1.4%
Q2 25	58M	+15.7%	+17.1%
Q3 25	66M	+13.7%	+32.8%
Q4 25	60M	-8.5%	+21.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	52
Q2 22	$0	52
Q3 22	$0	52
Q4 22	$0	70
Q1 23	$0	70
Q2 23	$0	70
Q3 23	$0	70
Q4 23	$0	88
Q1 24	$0	88
Q2 24	$0	88
Q3 24	$0	88
Q4 24	$0	106
Q1 25	$0	106
Q2 25	$0	106
Q3 25	$0	106
Q4 25	$0	200K

Revenue / Employee